F5 Q506 Mutation and the Low Prevalence of Cardiovascular Disease in Canadian Inuit

Journal of Investigative Medicine

Volumn 46, Issue 5, 1998, Pages 232-235

  Mandelcorn, Rochelle ^a   Connelly, Philip W ^a   Boright, Andrew ^a   Young, T Kue ^b   Hegele, Robert A ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Coagulation; Genetic predisposition; Polygenic disease; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5A;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CARDIOVASCULAR DISEASE; GENE FREQUENCY; GENETICS; HUMAN; MIDDLE AGED; MUTATION; PREVALENCE; THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CANADA; CARDIOVASCULAR DISEASES; FACTOR VA; GENE FREQUENCY; HUMANS; MIDDLE AGED; MUTATION; PREVALENCE; THROMBOSIS;

EID: 0032087537     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bjerregaard P, Dyerberg J. Mortality from ischemic heart disease and cerebrovascular disease in Greenland. Int J Epidemiol 1988;17:514-9.
2. Middaugh JP. Cardiovascular deaths among Alaskan natives. 1980-86. Am J Public Health 1990;80:282-5.
3. Young TK, Moffatt MEK, O'Neil JD. Cardiovascular diseases in a Canadian arctic population. Am J Public Health 1993;83:881-7.
4. Hegele RA, Young TK, Connelly PW. Are Canadian Inuit at increased genetic risk for coronary heart disease? J Mol Med 1997;75:364-70.
5. Hegele RA, Tully C, Young TK, Connelly PW. V677 mutation of methylenetetrahydrofolate reductase and cardiovascular disease in Canadian Inuit. Lancet 1997;349:1221-2.
6. Price DR, Ridker PM. Factor V Leiden mutation and the risks for thromboembolic disease: a clinical perspective. Ann Int Med 1997;127:895-903.
7. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbrouke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993;342:1503-6.
8. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
9. Holm J, Zoller B, Svensson PJ, Berntorp E, Erhardt L, Dahlback B. Myocardial infarction associated with homozygous resistance to activated protein C. Lancet 1994;344:952.
10. Marz W, Seydewitz H, Winkelmann B, Chen M, Nauck M, Witt I. Mutation in coagulation factor V associated with resistance to activated protein C in patients with coronary artery disease. Lancet 1995;345:526.
11. Rosendaal FR, Siscovick DS, Schwartz SM, Beverly RK, Psaty BM, Longstreth WT Jr, Raghunathan TE, Koepsell TD, Reitsma PH. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 1997;8:2817-21.
12. de Maat MP, Kluft C, Jespersen J, Gram J. World distribution of factor V Leiden. Lancet 1996;347:58.
13. Pepe G. Rickards O. Vanegas OC, Brunelli T. Gori AM, Giusti B. Attanasio M, Prisco D, Gensini GF, Abbate R. Prevalence of factor V Leiden mutation in nonEuropean populations. Thromb Haemost 1997;77:329-31.
14. Herrmann FH, Koesling M, Schroder W, Altman R, Jimenez Bonilla R, Lopacink S, Perez-Requejo JL, Singh JR. Prevalence of factor V Leiden mutation in various populations. Genet Epidemiol 1997;14:403-11.
15. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346:1133.
16. Ridker PM, Miletich JP, Hennekens CH, Buring JE. Ethnic distribution of factor V Leiden in 4,047 men and women. Implications for venous thromboembolism screening. JAMA 1997;277(16):1305-7.
17. Lee DH, Henderson PA, Blajchman MA, Prevalence of factor V Leiden in a Canadian blood donor population. Can Med Assoc J 1996;155:285-9.
18. Berliner JA, Navab M, Fogelman AM, Frank JS, Demer LL, Edwards PA, Watson AD, Lusis AJ. Atheroclerosis: basic mechanisms, oxidation, inflammation, and genetics. Circulation 1995;91:2488-96.
19. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med 1997;126:638-44.
20. Nordoy A. Haemostatic factors in coronary heart disease. J Intern Med 1993;233:377-83.
21. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries in coronary arteries of children and young adults. Arteriosclerosis 1989;9:119-32.
22. Nachman RL. Thrombosis and atherogenesis: molecular connections. Blood 1992;79:1897-1906.
23. Coughlin SR. Thrombin receptor structure and function. Thromb Haemost 1993;66:184-7.
24. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995;332:912-7.
25. Emmerich J, Poirier O, Evans A, Marques-Vidal P, Arveiler D, Luc G, Aiach M, Cambien F. Myocardial infarction, Arg 506 to Gln factor V mutation, and activated protein C resistance. Lancet 1995;345:321.
26. Ardissino D, Peyvandi F. Merlini PA, Colombi E, Mannucci PM. Factor V (Arg506 → Gln) mutation in young survivors of myocardial infarction. Thromb Haemost 1996;75:701.